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Abstract
Background: Vesicular stomatitis virus (VSV) causes severe losses to the animal husbandry industry. In this study, a
recombinant Newcastle disease virus (NDV) expressing the glycoprotein (G) of VSV (rL-VSV-G) was constructed and
its pathogenicity and immune protective efficacy in mouse were evaluated.
Results: In pathogenicity evaluation test, the analysis of the viral distribution in mouse organs and body weight
change showed that rL-VSV-G was safe in mice. In immune protection assay, the recombinant rL-VSV-G triggered a
high titer of neutralizing antibodies against VSV. After challenge, the wild-type (wt) VSV viral load in mouse organs
was lower in rL-VSV-G group than that in rLaSota groups. wt VSV was not detected in the blood, liver, or kidneys of
mice, whereas it was found in these tissues in control groups. The mice body weight had no significant change
after challenge in the rL-VSV-G group. Additionally, suckling mice produced from female mice immunized with
rL-VSV-G were partially protected from wt VSV challenge.
Conclusions: These results demonstrated that rL-VSV-G may be a suitable candidate vaccine against vesicular
stomatitis (VS).
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Background
Vesicular stomatitis (VS) is caused by the vesicular stoma-
titis virus (VSV), which belongs to the genus Vesiculovirus
of the family Rhabdoviridae and presents lesions in the
mucous membranes of the mouth and nose and the epi-
thelium of the feet and teats [1]. VSV has been detected in
swine, cattle, horses, and other animals in the U.S. several
decades ago [1]. In America, VSV has caused significant
economic losses due to decreased milk and meat produc-
tion, quarantines, trade barriers, and livestock market
closures [2, 3]. This virus could spread between hoofed
animals and rodents via insect vectors [4]. Vesicular
stomatitis in humans is a uniformly non-fatal influenza-
like illness [1].
Vaccination is preferentially used to prevent and control
the disease in human and animals [5–9]. Inactivated VSV
vaccines with aluminum hydroxide or oil as adjuvants have
been tested in the United States of America and in
Colombia according to the OIE Terrestrial Manual [10].
Additionally, a commercial bivalent inactivated VSV
vaccine containing antigens against the New Jersey (NJ)
and Indiana 1 (IND1) viruses were tested [11]. However,
to induce high levels of neutralizing antibodies and protect
animals from challenge by the virulent virus, the VSV anti-
gens need to be concentrated by ultracentrifugation on
sucrose gradient and then be inactivated [11], which is not
convenient for commercial production because it increases
costs and producing-process. Furthermore, immunization
with inactivated vaccine is indistinguishable from natural
VSV infection. The VSV Glycoprotein, which is the only
protein on the viral envelope, plays crucial roles in attach-
ment, fusion and entry into host cells [12]. G protein is
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highly immunogenic, and the target of neutralizing
antibodies [13–15]. Immune responses induced by the
expression of the VSV G subunit and DNA vaccines
were tested in the laboratory, however, DNA vaccines
couldn’t induce satisfactory neutralizing antibody titers
[16], and subunit vaccines in general do not prime ef-
fectively for cell mediated immunity [15]. Live-vectored
vaccines induce both humoral and cell-mediated im-
munity, which generally provide longer immune protec-
tion than inactivated or subunit vaccines [13, 14]. A
recombinant vaccinia virus expressing VSV G protein
provided partial protection against VSV challenge in
cattle [15]. The Newcastle disease virus (NDV) genome is
simple and easy to manipulate. It can be grown to high
titers in chicken embryos for vaccine production. It has a
strict host range and viral replication is restricted in mam-
mals [17]. Its safety has been demonstrated in many animal
models, including the African green monkey, rhesus mon-
key, pig, mouse, cattle, and chicken [18–26]. Its pre-
existing immunity and maternal antibody against mamma-
lian paramyxoviruses does not interfere with the replication
of NDV, because it is antigenically distinct from the mam-
malian paramyxoviruses. NDV has been actively developed
and used for the control of human and animal diseases in
recent years [18–22, 25–31].
In this study, a recombinant NDV expressing the G
protein of VSV was constructed. To the best of our
knowledge, this is the first study on a NDV-based VSV
vaccine. The pathogenicity and protective efficacy of
this recombinant virus were analyzed and the results
showed that the recombinant virus was safe in mice
and could induce high titers of neutralizing antibody
that protected adult or suckling mice from VSV
challenge.
Results
Expression of VSV G protein by rL-VSV-G
VSV Indiana strain G gene ORF was inserted between
P and M gene of NDV genome (Fig. 1a). rL-VSV-G
virus was recovered entirely from this cDNA using
established reverse genetics procedures [22]. To con-
firm the expression of VSV G, BHK-21 cells were in-
fected with rL-VSV-G at a MOI of 1. Cells infected
with rL-VSV-G or rLaSota total proteins were detected
by incubation with the monoclonal antibody against
VSV G by Western blot. The Western blot assay dem-
onstrated that rL-VSV-G reacted strongly with mono-
clonal antibodies against VSV G, producing a band of
about 60 kDa, which is equal to the molecular mass of
VSV G. However, the vector rLaSota did not react with
the VSV G monoclonal antibodies and no band was
detected (Fig. 1b). BHK-21 cells were also infected with
rL-VSV-G at a MOI of 0.01, and at 48 h after infection,
the cells were fixed and incubated with VSV G protein
monoclonal antibody (Sigma, USA) or mouse anti-NDV
antibody followed by staining with FITC-conjugated goat
anti-mouse antibody or TRITC-conjugated rabbit anti-
chicken antibody. Confocal immunofluorescence results
confirmed the expression of VSV G protein in infected
cells (Fig. 1c).
Furthermore, the genetic stability of VSV G gene in rL-
VSV-G was assessed by 10 serial passage of the virus in
SPF chicken eggs and confirmed by RT-PCR and immuno-
fluorescence assay. The results demonstrated VSV G gene
could be stably maintained and expressed (data not shown).
Pathogenicity in poultry and mice
To determine the pathogenicity of rL-VSV-G in poultry,
the mean death time (MDT), intracerebral pathogenicity
index (ICPI), and intravenous pathogenicity index (IVPI)
were determined in embryonated SPF chicken eggs or in
SPF chickens according to the OIE Manual (OIE) [32].
The results indicated rL-VSV-G kept nonvirulent in
poultry comparing with LaSota virus (data not shown).
The pathogenicity of rL-VSV-G was evaluated in mice
that had been treated using two different delivery routes,
intranasal instillation and intramuscular injection. The
mice were inoculated with rL-VSV-G or LaSota at a dose
of 107 TCID50 in 100 μl PBS and equal volume PBS was
intramuscularly injected or intranasally inoculated as
mock infection. Supernatant from homogenized tissues
was inoculated in BHK-21 cells, and viral load in these
tissues was determined by IFA.
The results show that all the mice inoculated with rL-
VSV-G by either of two routes did not develop adverse
reactions and and rL-VSV-G was not detected in the tis-
sues of the brain, spleen, lung, liver, heart, or kidney (data
not shown). There were no differences between rLaSota
or rL-VSV-G infection groups with respect to changes in
body weight after either intramuscular injection (Fig. 2a)
or intranasal instillation (Fig. 2b). These data suggested
that the VSV G inserting did not change the pathogenicity
of vector virus NDV in mice and that rLaSota and rL-
VSV-G had limited replication in major mice organs.
rL-VSV-G-induced high-level VSV-specific antibodies and
neutralizing antibodies in mice
Mice serum VSV-specific IgG, IgG1 and IgG2a were deter-
mined by ELISA after immunization. rL-VSV-G could
induce specific IgG against VSV (Fig. 3A-I). At fifth week,
rL-VSV-G group induced high level of IgG, IgG1, and
IgG2a (Fig. 3A-I), which indicated skewing of systemic ac-
tivity of T helper cell type 2 (Th2) and T helper cell type 1
(Th1) pathways, respectively. rL-VSV-G immunized mice
tended to produce a Th1-type immune response (IgG2a/
IgG1 > 1) (Fig. 3A-II), which may largely facilate the viral
clearance in mice [33].
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Fig. 2 Changes in body weight in mice inoculated with rL-VSV-G. Mice were (a) intramuscularly injected or (b) intranasally inoculated with 107
TCID50 of rL-VSV-G on day 0. Mice were observed and weighed daily from day −3 to day 14.. All mice survived the duration of the experiment.
Body weight changes for each group are shown as ratios of the body weight at day 0, which was set as 100 %
Fig. 1 Construction and identification of rL-VSV-G. a Schematic representation of the rLaSota genome and VSV G inserted between the P and M
genes. b Western blot assay of expression of VSV G. BHK-21 cells were infected with rLaSota or rL-VSV-G at a MOI = 1. After 24 h, cells were collected
and lysed, the cell lysate was separated by SDS-PAGE and immunoblotted with mouse anti NDV antibodies or VSV G monoclonal antibody.
c Immunofluorescence analysis of VSV G protein expression. BHK-21 cells were infected with rLaSota or rL-VSV-G at a MOI = 0.01. After 24 h, the cells
were fixed and then stained with chicken anti-NDV antibody or VSV G monoclonal antibody followed by incubation with FITC-conjugated goat
anti-mouse antibody or a TRITC-conjugated rabbit anti-chicken antibody
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The serum neutralizing (SN) antibodies against VSV
were detected in the rL-VSV-G group, and the titer was
1:2.25 at the first week after immunization (Fig. 3B-I). At
the second week after booster immunization, the SN titers
was 1:760 (Fig. 3B-I) in the rL-VSV-G group. SN antibody
titers induced by rL-VSV-G showed no dramatic increases
after challenge with wt VSV. This indicated that the wt
VSV replication could be limited in rL-VSV-G immunized
mice. The NDV SN titers were similar for both the rL-
VSV-G and rLaSota groups (Fig. 3B-II).
Assessment of protective efficacy of rL-VSV-G against wt
VSV challenge
At second week after the boost immunization, the mice
were challenged with wt VSV Indiana strain at 107 TCID50
by intranasal instillation. After challenge, no deaths or
typical symptoms of encephalitis were observed. Visible
fluctuations in body weight were observed in rLaSota and
PBS groups. There were no distinct changes in body
weight after challenge in the rL-VSV-G group (Fig. 4). The
mice were euthanized and the brains, lungs, livers,
spleens, kidneys and blood were collected daily from first
day one to day five after challenge. Viral titers in organs
were tested in the BHK-21 cells. Results showed lower
viral titers in the rL-VSV-G group than in other groups.
wt VSV was isolated only from the brains, lungs and
spleens of mice in the rL-VSV-G group, and viral titers
were lower than that in other groups (Fig. 5). The viral
load in rLaSota group was approximately equal to that of
the PBS group, and wt VSV were detected from day one
to day four after challenge.
Assessment of protective efficacy of rL-VSV-G in suckling
mice
Before challenge, the neutralizing antibody titer against
VSV for gravid mice was 1:512–1:1024 (data not shown)
in rL-VSV-G group. The survival rate of suckling mice
was 33 % in the rL-VSV-G group. In other groups it was
0 % (Fig. 6). In the rL-VSV-G group, some of the suck-
ling mice died from seventh day post-challenge, while no
mice died after the eighth day post-challenge. However,
suckling mice in the PBS group died on the fifth day
after challenge, and all died by seventh day. In the rLa-
Sota group, the suckling mice died on the fifth day post-
challenge and all died by eighth day. These results thus
demonstrated that rL-VSV-G could provide good pro-
tection against VSV for adult mice and partial protection
to suckling mice.
Fig. 3 Serologic responses assays in mice. Serum Ig G antibody subtype and neutralization analyses. The antibody titers for each group are
indicated as the means plus SD. (A-I) Quantity of IgG, IgG1, and IgG2a. (A-II) Ratio of IgG2a and IgG1. SN antibody titers for NDV and rL-VSV-G.
The serum samples were collected at different times after vaccination and the (B-I) VSV and (B-II) NDV SN titers were measured. Statistically
significant differences were determined using the t test. *, P < 0.05
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Fig. 4 Changes in the weight of mice challenged with wild-type VSV Indiana strain. Two weeks after the boost immunization, mice were challenged
with 1 × 107 TCID50 of wt VSV Indiana strain by intranasal instillation. Mice were weighed daily for 14 days
Fig. 5 Viral loading in different organs of mice challenged with VSV Indiana strain. The mice were euthanized and viral loading was determined
using inoculated BHK-21 cells from the (a) brain (b), lung (c), spleen (d), blood (e), liver, and (f) kidney in five days after challenge. Statistically
significant differences were determined using the t test. *, P < 0.05
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Discussion
Vesicular stomatitis virus (VSV) causes severe losses to
livestock industry and there are less available vaccines. The
viral vector NDV has been used in many animals, such as
African green monkey, rhesus monkey, pig, mouse, cattle,
and chicken, as well as in humans [20, 22, 23, 26, 28–30,
34]. NDV vectored vaccines can be grown to high titers in
embryonated chicken eggsand their safety and efficacy in
human and animals are well documented [20, 22, 23, 26,
28–30, 34]. In this study, the recombinant NDV expressing
VSV G (rL-VSV-G) was constructed. Our results showed
rL-VSV-G was safe and immunogenic for mice. rL-VSV-G
could induce high level of neutralizing antibody, which is
likely due to the NDV vector has been reported to elicit
strong innate immune responses in mammals [35, 36]. A
previously study reported the cattle were protected when
the SN titer was higher than 640 using vaccinia virus as
vector [15]. Our results demonstrated rL-VSV-G could
induce high level of neutralizing antibodies in mice (up to
760 after the second dose), thus we speculate the vaccine
could confer protection to the immunized animals. Of note,
immunization of susceptible animals such like pigs, cattle
and horses are planned in the future studies.
Live-attenuated VSV vaccines were reported, such as
neuro-virulence absence VSV with mutant M protein,
could induce similar level of antibody to that of wt VSV
[37]. A gene order re-arranged VSV which G gene was
moved from its promoter-distal position to the first
position in the genome [38]. The G protein expression was
elevated in infected cells but not in virus particles. This re-
arranged VSV induced higher neutralizing antibodies than
that of wt VSV, but the viral titers was approximate10-fold
lower than wt VSV. Compared with live-attenuated VSV,
NDV-vectored VSV vaccine have several advantages: it has
lower biosafety concerns; it is easy to culture and grow to
high titers in chicken eggs; it does not require complicated
cell culture equipment and are thermostable when lyophi-
lized. Most importantly, it will not interfere with natural
infection and vaccine immunization, thus can meet the
requirement of DIVA vaccine.
In the challenge study, the mice did not appear to suffer
any severe symptoms except for weight loss and convul-
sions in PBS group, however, these attenuated subclinical
signs were similar to those of previous reports [16]. None-
theless, the results regarding viral load in the tissues and
body weight change were determined and supported the
satisfactory the immune efficacy of rL-VSV-G.
To further examine the protective efficacy of recombinant
rL-VSV-G, passive immunity experiment was performed.
Obvious neurological symptoms including convulsions,
shuddering, and death were observed in the PBS and rLa-
Sota parental strain groups after challenge. However, the
suckling mice, which had maternal antibodies against VSV
showed attenuated clinical symptoms. In addition to this,
there were also fewer suckling mice with neurological
symptoms in the rL-VSV-G group than in other groups.
Additionally, differential roles of IgG subclasses in host
defense have been studied most extensively for IgG1 and
IgG2a, specifically addressing their ability to confer protec-
tion in models of viral and fungal infection [33, 39–41].
These studies have suggested that IgG2a is the most potent
subclass in mediating protection [33, 42]. rL-VSV-G immu-
nized mice tended to produce Th1 type immune response
(IgG2a/IgG1 > 1), which probably contributed to good
protective efficacy. In conclusion, all data demonstrated the
recombinant virus rL-VSV-G was highly safe and immuno-
genic in mice. rL-VSV-G could induce high level of neutral-
izing antibodies and thus confer good protection against
VSV challenge for mice. It appeared to be a promising
candidate vaccine against VSV.
Conclusions
Our results demostrated that rL-VSV-G could induce
high level of neutralizing antibodies and confer good
protection against VSV challenge for mice. It appeared
to be a promising candidate vaccine against VSV.
Methods
Cells and viruses
Baby hamster kidney (BHK-21) cells were grown in Dulbec-
co’s modified Eagle’s medium essential medium (DMEM)
containing 5 % fetal bovine serum (FBS). The NDV LaSota
as vector virus was rescued from the genomic cDNA of the
NDV LaSota vaccine strain (GenBank: AY845400.2) with
additional help from MVA-T7 [22, 23]. Recombinant NDV
strains, rLaSota and rLaSota expressing enhanced green
fluorescence protein (EGFP) (rLaSota- EGFP) were grown
and titrated in 10-day-old specific-pathogen-free (SPF)
embryonated chicken eggs by allantoic cavity inoculation.
Wild-type (wt) VSV (Indiana strain) and recombinant VSV
Fig. 6 Passive protection assay of maternal antibody in suckling
mice. Suckling mice were challenged with 103 TCID50 of VSV Indiana
strain by intranasal instillation on the 12th day after birth in a
Biosafety Level-3 laboratory. The number of dead mice was recorded
for 12 days after challenge
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expressing EGFP (rVSV-EGFP) were grown and titrated in
BHK-21 cells.
Rescue of recombinant virus
pBR322 containing NDV LaSota genomic cDNA have been
reported previously [22]. The open reading frame (ORF) of
G gene from VSV Indiana stain (Genbank Accession No.
J02428.1) was produced by reverse transcription (RT)-PCR.
Briefly, the VSV Indiana strain was grown in BHK-21 cells
at a multiplicity of infection (MOI) of 0.01 TCID50 per cell
over the course of 24 h (h), the supernatant was harvested
and VSV genomic RNA was extracted with a Total RNA
extraction Kit (OMEGA, Norcross, GA) according to the
instructions provided with the kit. The G gene was ampli-
fied by RT-PCR using the following primer pair:
5′-GACTGTTTAAACTTAGAAAAAATACGGGTA-
GAAGTACTGCCACCatgaagtgccttttgtac-3′ and 5′-GAC
TGTTTAAACttactttccaagtcggttcatc-3′, in which the gene
end and gene start sequences of NDV (underlined), the
optimal Kozak sequence (italic), the Pme I restriction sites
(bold) were introduced. The amplified G gene was se-
quenced and inserted into the LaSota genomic cDNA
between P and M gene. The resultant plasmid (designated
as pLa-VSV-G) was used for virus rescue as previously
described [22]. The resultant recombinant virus was desig-
nated as rL-VSV-G.
Immunofluorescence and western blot
The expression of G by the recombinant viruses was exam-
ined in BHK-21 cells by immunofluorescence and Western
blot assays, using a mouse monoclonal antibody against
VSV G protein (Sigma, U.S.) or chicken serum against
NDV as previously described [22]. To confirm the expres-
sion of G in the recombinant virus, Western blot was
performed using infected cell lysate. BHK-21 cells were in-
fected with rLaSota or rL-VSV-G at a MOI = 1. After 24 h,
the total cellular proteins were extracted with lysing buffer
(1 % Nonidet P-40, 0.4 % deoxycholate, 50 mMTris-HCl
[pH = 8], 62.5 mM EDTA) on ice for 5 min, and collected
in 1.5 ml Eppendorf tubes, followed by centrifugation for
2 min at 15,000 × g. the supernatant was stored at −70 °C
for Western blot analysis.
For confocal assay, BHK-21 cells were plated on cover
slips in 35-mm-diameter dishes and infected with rLaSota
or rL-VSV-G at a MOI = 0.01. The experimental proced-
ure was performed. Briefly, at 48 h after infection, the cells
were fixed and incubated with monoclonal antibodies
against VSV G or mouse anti-NDV polyclonal IgG
followed by FITC-conjugated goat anti-mouse antibody
(Sigma, USA) and TRITC-conjugated rabbit anti-chicken
antibody (Sigma, U.S.) [23]. Finally, cells were analyzed
with a fluorescence microscope or confocal laser micro-
scope. Images were acquired with a Zeiss Axioskop
Fluorescent Microscope (Thornwood, NY, U.S.). It was
equipped for epifluorescence with a Sensyscharge-coupled
device camera (Photometrics,Tucson, AZ, U.S.) by using
IPLab software (Scanalytics, Vienna, VA, U.S.).
Pathogenicity in poultry and mice
To determine the pathogenicity of rL-VSV-G in poultry,
the MDT, ICPI, and IVPI were determined in embryonated
SPF chicken eggs or in SPF chickens according to the OIE
Manual [43].
Forty-eight 4-week-old female Balb/c mice (Vital River,
Beijing, China) were inoculated with 107 TCID50 of rL-
VSV-G or rLaSota by intranasal instillation (30 μl, 107
TCID50) or intramuscular injection (100 μl, 10
7 TCID50).
Body weight was checked daily for 14 days. In five days
after inoculation, mice tissues were collected and homoge-
nized. Then viral tissue tropism was tested by indirect im-
munofluorescence (IFA) as described previously [22, 23].
Evaluation of immune protective efficacy of the
recombinant virus in mice
Eighty 4-week-old female mice (Balb/c) were randomly
divided into four groups, and the groups were named rL-
VSV-G, rLaSota, PBS, and naive control group, respectively.
Twenty mice from the rL-VSV-G group were immunized
with rL-VSV-G by intramuscular injection (100 μl, 107
TCID50). Twenty mice were mock-infected with PBS
(100 μl) and served as controls. An equal number of mice
were inoculated intramuscularly with rLaSota (100 μl, 107
TCID50). Booster immunization was performed at the third
week after primary immunization. Blood samples were col-
lected every week.
At second week after the boost immunization, the
mice were challenged with wt VSV Indiana strain at 107
TCID50 by intranasal instillation. This was performed in
a Biosafety Level 3 laboratory. The body weight and
symptoms of each mouse were monitored daily. The
mice were euthanized and their organs were collected
from first to fifth day after challenge and then stored in
– 70 °C. The viral titer was calculated in BHK-21 using
the Reed-Muench method [44].
Suckling mice immunization and challenge assay
Fifteen 8-week-old female Balb/c mice were randomly
divided into three groups. Five mice from each group were
intramuscularly immunized with rL-VSV-G, rLaSota or
PBS, according to an immunization program from above
study. After the first week of initial inoculation, female
mice from every group were allowed to share habitats with
male mice for two weeks. Mouse pups were born during
the fourth or fifth week after polyculture.
On the 12th day after birth, the suckling mice were
challenged with wt VSV Indiana strain at 103 TCID50 by
intranasal instillation in a Biosafety Level 3 laboratory.
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The mice were monitored for 12 days for death or any
clinical signs.
ELISA
Enzyme-linked immunosorbent assay (ELISA) and
neutralization assay were carried out to determine the
humoral immune responses of immunized mice. For
mouse serum, a previously reported procedure was used
[26]: 96-well ELISA plates were coated overnight at 4 °C
with inactivated purified VSV particles at a concentra-
tion of 4 μg/ml. The plates were then washed and
blocked with 2 % BSA-PBST (PBS containing 0.05 %
Tween-20 (v/v) and 2 % bovine serum albumin (BSA,
wt/v)) at room temperature for 1 h. Serially diluted
serum was added to the ELISA plate and incubated at
room temperature for 1 h. Plates were washed three
times with PBST, then a 1:4000 dilution of HRP-labeled
goat anti-mouse IgG (Southern Biotech, Birmingham,
AL, U.S.) was added and incubated for another 1 h at
room temperature. The plates were washed thoroughly
five times with PBST, and any remaining fluid was
decanted completely from each plate. For visualization,
50 μl of 3,3′,5,5′-tetramethylbenzidine (TMB) liquid
substrate (Sigma, U.S.) was added to each well for 5 min
at room temperature; 50 μl of 0.2 M hydrochloric acid
was added to stop the reaction. O.D. values were deter-
mined with a Model 680 microplate reader (Biorad) at
450 nm. A standard curve was generated by coating each
ELISA plate with serial 2-fold dilutions of purified
mouse IgG (Southern Biotech, Birmingham, AL, U.S.) at
specific concentrations. A linear equation was produced
based on the 2-fold decreased standard IgG concentra-
tion and their O.D. values, so the concentration of VSV
G protein-specific antibodies in each sample could be
calculated according to the linear equation using their
O.D. values and expressed as the amount of antigen-
specific IgG per ml of serum (ng/ml). As described
above, the concentration of serum IgG2a and IgG1 were
calculated and a similar process was performed.
Serum neutralizing antibody titration
For the neutralization assay, sera were heat-inactivated at
56 °C for 30 min. Serial two-fold dilutions were mixed with
equal volumes of virus were diluted to contain 500
TCID50/25 μl wt VSV-EGFP or 200 TCID50/25 μl rLasota-
EGFP. The mixture was incubated for 60 min at 37 °C in 5
% CO2. Then, 50 μl of the serum-virus mixture was trans-
ferred to BHK-21 cell monolayers in 96-well plates and
incubated for 1 h at 37 °C. The monolayers were then
added to 100 μl of DMEM. After incubation for 48 h at
37 °C, IFA was administrated. Neutralization titers were
expressed as the reciprocal of the highest dilution of serum
that showed at least a 50 % reduction in the number of
fluorescent cells relative to those of the negative control.
This assay was performed as in a previous work [23].
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